RPD Holdings, L.L.C. v. Tech Pharmacy Servs. (In Re Provider Meds, L.L.C.)

907 F.3d 845
CourtCourt of Appeals for the Fifth Circuit
DecidedOctober 29, 2018
Docket17-11113
StatusPublished
Cited by28 cases

This text of 907 F.3d 845 (RPD Holdings, L.L.C. v. Tech Pharmacy Servs. (In Re Provider Meds, L.L.C.)) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fifth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
RPD Holdings, L.L.C. v. Tech Pharmacy Servs. (In Re Provider Meds, L.L.C.), 907 F.3d 845 (5th Cir. 2018).

Opinion

PATRICK E. HIGGINBOTHAM, Circuit Judge:

RPD Holdings, L.L.C. claims that it purchased a patent license from multiple debtors in bankruptcy sales of their estates. Tech Pharmacy Services argues that RPD does not have rights under the license to Tech Pharm's patented invention. Concluding that the patent license was a rejected executory contract and could not have been transferred by the bankruptcy sales in question, we agree with Tech Pharm and affirm the decision of the district court.

I

This appeal emerges from a series of bankruptcy cases involving "OnSite." The entities involved in operating OnSite, the "OnSite parties," placed dispensing machines with long-term care facilities, then used proprietary OnSite software to remotely dispense pharmaceuticals from the machines to nurses in the facilities. They had a joint corporate parent, OnSiteRx, but functioned as independent business entities 1 -and, when the time came to file for bankruptcy, filed separate bankruptcy cases.

*849 A

The story begins before the OnSite parties filed for bankruptcy. Tech Pharm holds a patent on a system, software, and related methods of remote pharmaceutical dispensing. 2 In 2010, it sued multiple defendants in the Eastern District of Texas-including several OnSite parties-for infringing this patent by using their own remote pharmaceutical dispensing machines. 3 The OnSite parties counterclaimed challenging Tech Pharm's patent. The parties agreed to settle the litigation, entering into a "Compromise, Settlement, Release, and License Agreement" (the "License Agreement"), granting a "non-exclusive perpetual license" to all but one of the OnSite parties for "so long as the Patent or Patents are valid and enforceable." The OnSite parties agreed to pay a one-time licensing fee of $4,000 for each OnSite machine placed into operation after the execution of the agreement, and to provide quarterly reports reflecting all new machines placed in service. All parties also agreed to release any and all claims they "may have or claim to have ... which relate to or could have been claimed in the Litigation, or that relate to the [Patents] or any alleged infringement [or invalidity] of same, except for the obligations specifically called for under this Agreement." Following the settlement agreement, the district judge in the Eastern District of Texas dismissed all claims with prejudice.

B

Beginning in 2012 and continuing into 2013, the six OnSite parties relevant to this appeal filed separate Chapter 11 bankruptcy cases in the Northern District of Texas. 4 Each case was later converted to Chapter 7. Five of the six OnSite debtors were also parties to the Tech Pharm License Agreement. Despite the bankruptcy requirement that they schedule all assets and creditors, however, none of the debtors listed the License Agreement or Tech Pharm on their schedules.

RPD had a security interest in the OnSite debtors' collateral. It agreed to purchase its collateral from three of the bankruptcy estates-ProvideRx of Grapevine, LLC ("Grapevine"), ProvideRx of Waco, LLC ("Waco"), and W. Pa. OnSiteRx, LLC ("Western Pennsylvania")-instead of litigating its liens. RPD and each estate laid out the terms of each sale in a separate asset purchase agreement, the APA, and each sale was approved by the bankruptcy court in a separate sale order. No APA explicitly referenced the License; instead, each APA covered certain categories of subject property. In turn, the sale orders approved the sale of the subject property in each APA-providing that to the extent that any of the subject property was an executory contract, it was "hereby ASSUMED by the Estate and immediately ASSIGNED to RPD under the applicable provisions of section 365 of the Bankruptcy Code." The parties have stipulated that RPD was not aware of the License until after all three sale motions and APAs were filed with the bankruptcy court, but that it became aware of the License before the bankruptcy court entered the last of the sale orders, the Waco sale order.

Shortly after the bankruptcy court approved the last of these sales, the trustees from the other estates-Provider Meds, LP ("Provider Meds"), OnSiteRx, Inc. ("OnSite"), and ProvideRx of San Antonio, *850 LLC ("San Antonio")-entered into a settlement agreement, the "global agreement," with RPD and CERx, a competing secured party. The global agreement provided for RPD and CERx to severally own the OnSite source code, and divided other assets between them. RPD avers that because it was aware of the License at this point, it believed that it had purchased the License under the terms of the Grapevine, Western Pennsylvania, and Waco APAs and sale orders. As a result, the global agreement provided that the Provider Meds and San Antonio trustees would transfer their Tech Pharm licenses to CERx, but that "RPD is entitled to all remaining available Tech Pharm licenses (such as those otherwise acquired from ProvideRx of Grapevine, LLC; W Pa OnsiteRx, LLC; and ProvideRx of Waco, LLC)."

C

Almost a year after the bankruptcy court approved the global agreement, Tech Pharm filed a petition in Texas state court against several defendants, including the Waco and San Antonio debtors, alleging that the defendants had failed to comply with their obligations under the License Agreement to provide quarterly reports and pay licensing fees for new machines. RPD intervened and removed the proceeding to the bankruptcy court, arguing that one or more of the debtor estates had assigned or otherwise transferred the License to RPD.

The bankruptcy court held that RPD did not have rights under the License Agreement for either of two reasons: RPD had not purchased the License under any of the OnSite sales and, regardless of the terms of the sales, the License Agreement was an executory contract that was rejected by operation of law prior to any alleged transfer. 5 It also determined that RPD had not gained rights under the License Agreement by purchasing OnSite machines from the debtors. 6 RPD appealed to the district court, which concluded that the License was a rejected executory contract and affirmed. 7

RPD now appeals the decision of the district court affirming the bankruptcy court. It claims that its rights under the License Agreement were established by final and non-appealed bankruptcy court orders, so any determination to the contrary would constitute an impermissible collateral attack. It also argues that the bankruptcy and district courts erred on the merits in determining RPD has no rights under the License Agreement.

D

In reviewing a decision of the district court affirming the bankruptcy court, we apply "the same standard of review to the bankruptcy court that the district court applied," reviewing findings of law de novo and findings of fact for clear error. 8

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
907 F.3d 845, Counsel Stack Legal Research, https://law.counselstack.com/opinion/rpd-holdings-llc-v-tech-pharmacy-servs-in-re-provider-meds-llc-ca5-2018.